Serious adverse events: None reported in published research
Additionally, refrain from strenuous exercise and invasive skincare treatments for a short period, and follow your doctor's specific instructions for optimal outcomes
This combination medicine belongs to a class of nutritional supplements
SKU: 26-K762-100 Availability: Usually shipped in 5 working days Size: 100 Assays Alternate Name: N/A Tag Line: N/A Storage: -20C Shipping: Gel Pack Detection Method: N/A Category: Glutathione reductase Species Reactivity: N/A Sample Type: Cell and tissue culture supernatants, urine, plasma and serum, erythrocyte lysates, as well as many other biological fluids, etc
The phase 1 clinical trials evaluated escalating doses of CB-839 in patients with advanced solid tumors among the patients with triple-negative breast cancer, RCC, mesothelioma, NSCLC, fumarate hydratase (FH)-deficient tumors, succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) or non-GIST tumors, cMyc-mutated tumors, and isocitrate dehydrogenase-1 (IDH1)- or IDH2-mutant tumors in combination with standard of care chemotherapy
